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ABSTRACT Amantadine is known to block the M2 proton channel of the Inﬂuenza A virus. Here, we present a structure of the
M2 trans-membrane domain blocked with amantadine, built using orientational constraints obtained from solid-state NMR
polarization-inversion-spin-exchange-at-the-magic-angle experiments. The data indicates a kink in the monomer between two
helical fragments having 20 and 31 tilt angles with respect to the membrane normal. This monomer structure is then used to
construct a plausible model of the tetrameric amantadine-blocked M2 trans-membrane channel. The inﬂuence of amantadine
binding through comparative cross polarizationmagic-angle spinning spectrawas also observed. In addition, spectra are shownof
the amantadine-resistant mutant, S31N, in the presence and absence of amantadine.
INTRODUCTION
Inﬂuenza is a worldwide epidemic that causes substantial
morbidity and mortality. Of the three types of inﬂuenza
viruses—A, B, and C—only Inﬂuenza A and B can cause
epidemic diseases. Amantadine (1-adamantanamine hydro-
chloride) and its analog rimantadine (Fig. 1) are licensed
drugs in the United States and Europe. Both drugs have been
used in the prophylaxis and treatment of inﬂuenza A viral
infections. Unlike zanamivir and oseltamivir, which are neur-
aminidase inhibitors, amantadine and rimantadine act on the
M2 proton channel in the membrane of the inﬂuenza A virus.
Amantadine is generally believed to block the M2 channel in
a manner similar to the interaction of quaternary ammonium
blockers with various ion channels (1), and consequently
stunts the replication of the Inﬂuenza A viruses in host cells.
During the past inﬂuenza season, 94% of Inﬂuenza A mu-
tated to an amantadine resistant (S31N) form (2).
The M2 proton channels function as pH modulators at two
stages in viral replication. Initially, viruses enter cells via
endocytosis, i.e., the host cell membrane engulfs a virus and
forms an endosome. In this acidic compartment (pH 5–6), the
opening of the M2 channel imports protons into the viron,
triggering a change in protein-protein and protein-membrane
interactions that leads to the uncoating of the viral particle. In
a late stage of infection, newly synthesized M2 proteins form
channels in the trans Golgi network and balance the pH
gradient across the membrane. In this case, the channel ex-
ports protons from the trans Golgi lumen to the cytoplasm.
The inhibitory efﬁcacy of amantadine is directly associated
with the function of the M2 channel in that the presence of
amantadine results in the failure of viral uncoating (the early
stage) and the premature conformational change of hemag-
glutinin (the late stage).
The M2 protein (97 amino-acid residues) is an integral
membrane protein with a single trans-membrane (TM) helix.
The functional M2 channel is a homotetramer (3) stabilized
in part by disulﬁde bonds linked between the N-terminal cys-
teines near the membrane interface. The M2 protein exhibits
proton conductivity in a variety of artiﬁcial and natural mem-
brane systems such as oocytes (3), mammalian cells (4), and
even lipid bilayers (5). Consistently, the proton conductance
is inhibited by a few mM amantadine or rimantadine, except
in very low pH lipid bilayer preparations. Measurement of
the proton current decay as a function of the amantadine con-
centration suggests that one drug molecule binds to one M2
tetramer with an apparent Kd of 0.3 mM (3).
The functional core of the channel is a TM domain (TMD)
consisting of four a-helices. Evidence shows that the 25-re-
sidue M2-TMD polypeptides (S22SDP-LVVAASIIGILH-
LILWILDRL46) spontaneously form amantadine-sensitive
proton channels once they are incorporated into lipid bilayers
(6–9). The M2-TMD structure in lipid bilayers determined
by solid-state NMR spectroscopy clearly displays an aque-
ous pore in the center that is most likely responsible for the
proton conduction (10–14). In this structure, four helices tilt
at ;38 with respect to the bilayer normal and form a left-
handed bundle with polar residues (e.g., His37 and Trp41)
oriented toward the channel lumen (PDB code 1nyj). This
structure is consistent with the cysteine scanning mutagen-
esis and electrophysiological studies of the M2 protein
(15,16). The TM helices of the intact M2 protein, however,
appear to orient in lipid bilayers with a somewhat smaller tilt
angle of ;25 (17).
The ﬁrst M2/amantadine model was proposed by Sugrue
and Hay (18,19). It was based on an analogy of the dis-
tribution of the amantadine-resistant M2 mutations with that
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of the mutations in the nicotinic acetylcholine receptor. The
key feature of this model emphasizes the interaction between
the amantadine amino group and the Ser31 hydroxyl group.
This interaction was adopted later in the molecular modeling
of the M2-TMD/amantadine complex (20). Recent structures
of the M2-TMD provide more insight into amantadine bind-
ing, particularly that the pore volume is sufﬁcient to accom-
modate an amantadine molecule. Taking advantage of these
structures and analytical ultracentrifugation results for the
M2-TMD mutants, Stouffer et al. (21) constructed a recent
model that was very similar to that of Sugrue and Hay.
Another model, proposed by Gandhi et al. (23), focuses on
the possible H-bond interaction between the amantadine
ammonium group and the nonprotonated nitrogen atoms on
the His37 side chains. In all of these models, the adamantyl
group of amantadine is believed to reside closer to the ex-
ternal surface of the viral membrane, consistent with the map
of the amantadine-resistant mutations. Additionally, Astrahan
et al. (24) suggested a model based on the Nishimura model
(11) and surface plasma resonance spectroscopy of amantadine-
insensitive mutants to explore the resistance mechanism of
the M2 mutants.
Although it is natural to deduce the M2-TMD/amantadine
complex on the basis of the ligand-free structure, both ﬂuo-
rescence spectroscopy and circular dichroism provide evidence
for subtle structural changes in the presence of amantadine (25).
In addition, Gandhi’s energy-minimized model suggests that a
structural rearrangement occurs upon amantadine binding (23).
Titration of the His37 side chain from M2-TMD monitored by
15N CP/MAS NMR clearly demonstrates decreased proton
afﬁnity and restricted motion in the presence of amantadine
(26). Here, we report the inﬂuence of amantadine binding on
the M2-TMD NMR spectra. We then derive structural orien-
tation restraints for M2-TMD in the presence of amantadine
from a series of polarization-inversion-spin-exchange-at-the-
magic-angle (PISEMA) experiments (27,28) performed on uni-
formly and selectively labeled aligned samples. Each labeled
15N backbone atom gives geometric information about the cor-
responding peptide plane. We use the data to build an atomic
structure of the monomer, and then construct a tetrameric
model of the ligand-bound M2-TMD. The tetrameric nature of
M2-TMD has been suggested by both ultracentrifugation (25)
and solid-state NMR (7).
MATERIALS AND METHODS
Sample preparation
All 15N labeled amino acids were purchased from Cambridge Isotope
Laboratories (Cambridge,MA). Single ormultiple-site 15N labeledM2-TMD
samples were synthesized and incorporated into DMPC/DMPG liposomes as
described previously (9). For an M2-TMD sample with 10 mM amantadine,
46.9 mg amantadine (250 mmol) hydrochloride (Fisher Scientiﬁc, Suwanee,
GA) in 5ml citrate-borate-phosphate (CBP) buffer was added to anM2-TMD
loaded vesicle suspension (20 ml). The suspension was incubated at room
temperature overnight and pelleted by ultracentrifugation (196,000 g). The
M2-TMD in DMPC/DMPG liposomes with or without amantadine was
packed into a 7mmBruker zirconia spinner (Billerica,MA)with a sealing cap
designed for magic-angle spinning (MAS) NMR experiments.
Oriented samples of the peptide in hydrated DMPC bilayers were
prepared by ﬁrst co-dissolving M2-TMD (;120 mg) and DMPC (;75 mg)
in 10 ml TFE. TFE was removed by rotary evaporation and dried further
under high vacuum. CBP buffer, 15 ml, 2 mM (;37C, pH 8.8) with 1 mM
EDTA, was added to the dried mixture and shaken in a shaker bath at 37C,
which is higher than the gel-to-liquid-crystalline phase transition temper-
ature of DMPC of;23C (29). This lipid suspension was bath-sonicated for
10 min intermittently. The sonicated suspension was then loaded into a
1 kDa MW cutoff dialysis bag. The dialysis bag was placed in a 1 L volume
of 2 mM CBP buffer (pH 8.8) overnight to equilibrate the pH between the
M2-TMD/DMPC liposomes and the outside buffer. For the samples with
amantadine, the outside buffer contained 10 mM amantadine. The liposomes
were passed through a 2 mm ﬁlter and pelleted by ultracentrifugation at
196,000 g. The pellet was agitated at 37C for 1 h until ﬂuid. This thick ﬂuid
was spread onto 50 glass slides (5.7 mm3 12.0 mm) (Marienfeld Glassware,
Bad Margentheim, Germany) and dehydrated in a 70–75% humidity
chamber. The dehydrated slides were rehydrated with 1.5 ml 2 mM CBP
buffer followed by being stacked into a glass tube. The sample was incubated
at 43C for 24 h in a 96% relative humidity (saturated K2SO4) chamber.
Finally, the glass tube was sealed at both ends with epoxy and two glass caps.
Solid-state NMR experiments
All CPMAS NMR experiments were performed on a Bruker DMX-300 NMR
spectrometer with a 7 mm rotor Bruker triple resonance MAS probe. The 15N
CPMASspectrawere recordedwith a 5 s recycle delay at a resonance frequency
of 30.418MHz, 277 K, and a spinning rate of 3 kHz. After a 90 pulse of 7 ms
applied on the 1H channel, an optimized 2 ms contact time was used for cross
polarization followed by high power continuous wave proton decoupling
during acquisition. 10 K scans were accumulated for each experiment and a
100 Hz exponential line broadening was applied to the free induction decay
before Fourier transformation. Two-dimensional PISEMA experiments were
performed on a 9.4 Tesla magnet with a Bruker Advance console using a
homebuilt 15N/1H double-resonance probe. The air temperature ﬂowing
through the NMR sample tube was set to 298 K by an XR401 sample cooler
(FTS Systems, Stone Ridge, NY). The rate of airﬂow was 500 l/h. Typically, a
6 s recycle delay was applied before the initial 1H 90 irradiation pulse with a
radio-frequency (RF) ﬁeld of 52.1 kHz. This RF ﬁeld was also applied during
the 1H-15N cross polarization (800 ms) and 1H continuous wave decoupling,
while anRFﬁeld of 63.7 kHzwas usedduring the Lee-Goldburg spin exchange
at the magic angle. Thirty-two T1 increments with 512 or 1024 scans were
recorded for two-dimensional PISEMA spectra. 15N chemical shift of a
saturated 15NH4NO3 was referenced as 0 ppm for all
15N chemical shifts.
NMR data simulations, structural calculations,
and reﬁnement
Standard peptide plane geometry (30) with average magnitudes and orien-
tations for backbone amide 15N chemical shift tensors (a¼ 0, b¼ 17,s11¼
31 ppm, s22¼ 55 ppm, and s33¼ 202 ppm) were used throughout our NMR
data analysis (14,31–33). For the His37 and Trp41 side-chain 15N chemical shift
FIGURE 1 The structure of Amantadine and its analog Rimantadine.
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tensors, values were obtained from Ramamoorthy et al. (34). The dipolar
coupling constant for the 15N-1H interaction was computed to be 21.47 kHz.
Torsion angle values for ideal a-helices (f ¼ 60, c ¼ 45) were used in
polar-index-slant-angle (PISA) wheel, PISEMA wave, and PISA helix
simulations, which were described previously (26,33,35–39). All PISA wheel
and PISEMA wave data analyses were performed using Maple 8 (MapleSoft,
Waterloo, Ontario, CA).
An initial backbone structure for the M2-TMD monomer was built by
ﬁtting the PISEMA spectra with an ideal a-helix having a kink connecting
twohelical fragmentswith different tilt angleswith respect to the bilayer normal
that were deduced from PISA wheels (Fig. 4). Side chains were added from a
rotamer library using SCWRL3.0 (42). To ensure proper stereochemistry,
energyminimizationwas performed on all atoms usingXPLOR-NIH (43)with
the following stereochemical energy terms: bonddistance, bond angle, dihedral
angle, and improper dihedral angle. Each stereochemistry termwas minimized
individually in the order listed. Finally, nonbonded energy terms were added,
consisting of a van der Waals energy term, two energy terms that reﬂect the
experimental solid-state NMR energy (44), and a hydrogen-bonding term (45).
All energy termswereweighted to beof the sameorderofmagnitude.The solid-
state NMR potentials used are of the form
Ecs ¼ +
cs
ðsc  soÞ2; (1)
Edp ¼ +
dp
ðnc  noÞ2; (2)
where sc is the calculated chemical shift from the model, so is the observed
chemical shift, and nc and no are the calculated and observed values of the
dipolar coupling, respectively. The hydrogen-bonding potential is a semi-
empirical force ﬁeld that consists of distance and angular components (45).
These potentials were implemented as Python (the Python programming lan-
guage, http://www.python.org/) modules into the XPLOR-NIH reﬁnement
package. The modules are freely available at http://www.math.fsu.edu/
;bertram/software/sb.
An initial M2TMD/amantadine homo-tetramer model was built by sym-
metric transformations of the energy-minimized monomer, which yielded
minimal helix-helix interaction energy, as measured by the XPLOR-NIH
van der Waals potential. The tetrameric initial model was then energy-
minimized using the same procedure performed on the monomer.
RESULTS
Spectral change upon amantadine binding
Drug or ligand binding to a protein commonly perturbs the
structure and the chemical environment of the binding site,
thereby shifting both the isotropic and anisotropic chemical
shifts, in oriented systems, of those residues near the binding
site. We conducted 15N CPMAS experiments of 15Nd1 His37
M2-TMD in liposomes with and without amantadine (Fig. 2
A). The resonances at 230 ppm and 147 ppm are assigned to
the nonprotonated 15Nd1 signal and protonated 15Nd1 signal,
respectively, based on previous analyses (22). Both spectra
of samples in the presence and absence of ligand observed at
pH 8.8 indicate that His37 side chains are neutral. The peaks
in the NMR spectrum with amantadine are much narrower
than those without amantadine; the presence of amantadine
reduces the signal line width by approximately a factor of
two. Despite the change in line width, the isotropic chemical
shifts for these two resonances are not signiﬁcantly affected by
the introduction of amantadine, suggesting little, if any, direct
interaction between the amantadine amino group and the
His37 nonprotonated Nd1, as suggested by Gandhi et al. (23).
The reduction of signal linewidth in the presence of
amantadine is also reﬂected in the 15N anisotropic chemical
shift spectra and PISEMAspectra of 15Na leucine labeledM2-
TMD (Fig. 2, B and C). The change in anisotropic chemical
shift frequencies in the PISEMA spectra (Fig. 2 C) indicates
that M2-TMD has a modiﬁed conformation once amantadine
binds to the channel. The high-resolution PISEMA data al-
lows us to characterize the backbone structure of M2-TMD/
amantadine. Although the ﬁve 15N signals are severely over-
lapped in the one-dimensional spectrum (Fig. 2 B, bottom
spectrum), four of ﬁve resonances are well resolved by the
dipolar-coupling dimension in the PISEMA spectrum.
During the 2005–2006 ﬂu season, 94% of the reported
Inﬂuenza A cases were resistant to amantadine through the
S31N mutation (2). A spectral comparison of this mutant
with and without amantadine (Fig. 3) shows little conforma-
tional change in the backbone and no characteristic change in
line width as seen in Fig. 2. This is consistent with our results
that show a signiﬁcant change when amantadine binds to the
wild-type M2 and hence we conclude that amantadine does
not bind to this amantadine resistant mutant. Furthermore,
the data suggests a much greater tilt angle for the C-terminal
FIGURE 2 Spectral comparison of the M2-TMD
with (bottom) and without (top) amantadine. (A)
CPMAS NMR spectra of 15Nd1-His37 M2-TMD in
DMPC/DMPG liposomes at pH 8.8 and 277 K.
Asterisks indicate spinning side bands. (B) Static
15N spectra of 15N-(L26, L36, L38, L40, L43)
M2-TMD uniformly aligned in DMPC bilayers at
pH 9 and 298 K. (C) PISEMA spectra for the sam-
ples used in panel B.
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region of the transmembrane helix than observed in the wild-
type when amantadine is bound.
Structure of the M2-TMD monomer in the
presence of amantadine
The resonance distribution of aligned helical proteins in
PISEMA spectra follows a unique pattern called a polar-
index-slant-angle (PISA) wheel (33,35,37). Two important
structural properties—helical rotation angle and tilt angle—
can be deduced by ﬁtting the PISEMA spectrum with PISA
wheels. This PISA wheel analysis provides a convenient tool
to analyze membrane protein PISEMA spectra since the
transmembrane domains of membrane proteins are predom-
inantly a-helical (46,47).
Fig. 4 shows the PISEMA spectra from multiple and
single-site backbone 15N labeled M2-TMD with amantadine
in uniformly aligned lipid bilayers. Two side-chain 15N
resonances, 15Ne1  Trp41 and 15Ne2  His37, are also shown
in Fig. 4, E and F. The Ne2 site in His37 is protonated more so
FIGURE 3 Spectral comparison of the M2-TMD
S31N mutant with (bottom) and without (top) aman-
tadine. (A) Static 15N spectra of 15N-(L26, L36, L38,
L40, L43) M2-TMD uniformly aligned in DMPC
bilayers at pH 9 and 298 K. (B) PISEMA spectra for the
samples used in panel A.
FIGURE 4 PISEMA spectra for 15N labeledM2-TMD samples uniformly aligned in DMPC bilayers in the presence of 10 mM amantadine at pH 8.8 and 308
K. Each panel shows data from separate selective labelings: (A) isoleucines; (B) leucines; (C) glycine, alanines, valines; and (D) tryptophan. Panels E and F are
the data from side chain 15N of W41 and H37, respectively.
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at pH 8.8 than the Nd1 site due to the predominance of this
tautomeric state. Interestingly the Trp41 resonance appears at
0 kHz and at the isotropic chemical shift. A large anisotropy
has been determined for this site (data not shown) and con-
sequently these isotropic values are not the result of dynamics,
but of a fortuitous orientation.
The sequential resonance assignments for the backbone
were conﬁrmed by PISEMA spectra of single-site 15N labeled
samples (data not shown). Fitting the full PISEMA data set
with a single PISA wheel failed due to the wide resonance
distribution, but introducing two PISA wheels with 20 and
31 tilt angles agree well with the PISEMA resonances (Fig. 5
A). Dipolar wave (38,39) and chemical shift wave (36)
simulations that include the 100 rotation per residue conﬁrm
the existence of two tilt angles (Fig. 5 B). These analyses
suggest that the M2-TMD/amantadine helix has a small
(;11) kink that occurs between residues G34 and L36. In
addition, the dipolar waves clearly show that there is no
change in the phase of the wave at the kink site, so the rota-
tional orientation remains the same with or without the kink.
In Fig. 5 C, we illustrate another method of ﬁtting the
PISEMA data: the PISA helix. The PISA helix is a com-
bination of dipolar wave, chemical shift wave, and PISA
wheel simulations presented in a three-dimensional space.
For an ideal a-helix, the PISA helix function maps a right-
handed helix, resembling its helical origin. Moreover, dif-
ferent tilt angles result in PISA helices with different size and
shape, providing another sensitive analysis of PISEMA data.
An initial model for the M2-TMD/amantadine monomer
was built using two ideal a-helices, which matched the
dipolar and chemical shift waves derived from the assigned
PISEMA spectra. The structure contained a kink near Gly34
that breaks the a-helical i–(i14) hydrogen bonding in this
region (Fig. 5 B). We energy-minimized this initial model
with weighted stereochemical and experimental potentials.
The experimental potentials consisted of 15N anisotropic che-
mical shift and 15N-1H dipolar coupling pairs, which provide
orientational constraints (44). The structure and simulated
PISEMA data ﬁtting of the resultant M2-TMD/amantadine
monomer is shown in Fig. 6.
M2-TMD/amantadine tetramer model
Wemodeled the M2-TMD/amantadine tetramer as a series of
rigid-body transformations of the monomer subunit. Building
a homotetramer using a monomer derived from NMR data
requires resolving two degrees of freedom: the interhelical
distance and the monomer rotation with respect to the bilayer
normal. The interhelical distance (helix axis to helix axis at
the crossing point of the helices) of the tetramer model was
initially taken to be 10 A˚, which is typical of four-helix
bundles (48) and similar to the structure without amantadine
(11). The rotational ambiguity was resolved by sampling
symmetric rigid-body rotations of themonomer and recording
the helix-helix interaction energy. This conformational search
was performed by rotating all subunits of the tetramer in 5
increments, and recording the van derWaals potential energy.
The energy proﬁle (Fig. 7) contains two minimal regions, A
and C, corresponding to right-handed and left-handed bun-
dles, respectively. In the absence of data to suggest a change
in handedness from the ligand-free structure and assuming
that hydrophilic residues continue to energetically favor the
FIGURE 5 (A) Two PISA wheels in the M2-TMD PISEMA spectrum. Experimental PISEMA resonances are connected with lines based on resonance
assignments. The PISEMA resonances are ﬁtted with two PISAwheels with tilt angles of 20 and 31. Question marks indicate the missing data points and their
hypothetical positions. (B) PISEMA wave simulations of the 15N M2-TMD anisotropic chemical shifts and 15N-1H dipolar couplings. (C) PISA helix ﬁtting of
the M2-TMD/amantadine PISEMA data. Two helices are ﬁtted with 20 (green) and 31 (magenta) tilt angles. The curve-ﬁtting x2 values are 1.65 and 6.86 for
the dipolar couplings and the anisotropic chemical shifts, respectively.
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channel interior, the M2-TMD/amantadine tetramer was cho-
sen tobe the left-handedbundlewith theminimal vanderWaals
energy (i.e., from region C). This tetramer was then energy-
minimized in the same manner as the monomer.
The reﬁned amantadine/M2-TMD complex is shown in
Fig. 8. It is a left-handed helical bundle that is radially sym-
metric about the center of the channel with an average channel
width of;10 A˚. The structurewithout ligand is similar in these
characteristics (11), but the kink in the amantadine-blocked
model results in a tightening of the channel near theN-terminus
and awideningof the channel near theC- terminus (Fig. 8C). In
Fig. 8 B, we show a top-down view of the reﬁned model along
with a reasonable positioning of the blocking amantadine
molecule. Our data did not contain information about the
amantadine location.
DISCUSSION
The data presented in Fig. 2 demonstrate that amantadine
binds to M2-TMD in our bilayer preparations both for magic
angle spinning and for aligned samples based on the dra-
matic improvement in linewidth. Furthermore, the binding of
amantadine to our preparations strongly suggests that our
preparations of M2-TMD form a pore in which amantadine
binds. Such a pore is likely to be formed by a tetrameric
structure. Although, the MAS spectral resonance intensi-
ties are not quantiﬁed here for 15Nd1 M2-TMD with bound
amantadine, both protonated and deprotonated states are
observed (Fig. 2 A, bottom), suggesting a certain level of
chemical heterogeneity; yet, there is no evidence for multiple
chemical shifts or dipolar couplings among the structural
restraints. Indeed, the spectra may suggest considerably less
heterogeneity when M2-TMD is bound to amantadine, as
compared to the structure without the drug. The broad reso-
nance lines observed in the absence of amantadine may be
the result of efﬁcient relaxation due to slow motions, or
possibly the result of conformational heterogeneity. Previ-
ously, in studies of the full-length protein, ‘‘rotational ex-
cursions’’ have been described to account for the complete
H/D exchange of the transmembrane helix in planar bilayers
(17). While our data does not rule out either prospect, it is
clear that the presence of amantadine reduces the structural
or sample heterogeneity. In addition, it appears as if the struc-
tural stability is enhanced through the binding of amantadine
to M2-TMD.
FIGURE 6 (A) Backbone stick structure of one M2-TMD subunit with amantadine (amantadine not shown) based on PISEMA data from residues 26–43.
Plausible positions of residues His37 and Trp41 side chains constrained by PISEMA side-chain data are also shown, but their positions are not unique. (B)
Comparison between experimental PISEMA resonances (open squares) and the simulated PISEMA resonances (solid circles) of the reﬁned M2-TMD/
amantadine structure shown in panel A. The solid line is the PISEMA ellipse, which represents the range of possible values within the chemical shift and dipolar
tensors. (C) The monomer structure with cylinders along the helical fragment axes emphasizing the 11 kink near Gly34.
FIGURE 7 The energy landscape of the M2TMD homotetramer. Sym-
metric rigid body monomer rotations were performed about the membrane
bilayer normal, here represented as the Z axis. The graph gives a relative
measure of helix-helix interaction energy. The ﬁgures at the top of each region
are representative conformations for the region, with arrows indicating the
average tilt direction.
4340 Hu et al.
Biophysical Journal 92(12) 4335–4343
It has been proposed that the amino group of amantadine
binds His37 (23), Ser31 (20), or Asp24 (49). If such interactions
take place, the lack of multiple resonances for the backbone
sites between Leu26 and His37 suggests that the structure is
time-averaged—implying that any interacting residues from
separate monomers (e.g., four His37, four Ser31, etc.) are in-
volved equally.
The PISEMA data are very sensitive to structural deforma-
tions. For example, an orientational change as small as 4 can
produce a 20ppmchange in chemical shift or a 2 kHz change in
dipolar coupling. The uniformity of our data (e.g., ﬁt to dipolar
and chemical shift waves) suggests that, in addition to any
improved structural stability of the channel caused by aman-
tadine, the structure is undergoing a time-averaged conforma-
tional change that maintains the apparent fourfold symmetry of
the structure. The data for His37 and Trp41 side chains indicate
that the structural symmetry possibly extends beyond the back-
bone to the side chains, at least at these high pH values.
The chemical shift and dipolar waves of the structure show
a kinked structure with different helical tilts with respect to
the magnetic ﬁeld axis and the bilayer normal. In addition,
there is only a minor change in the phase of the waves, indi-
cating that it is a simple kink and not a p-bulge or other more
signiﬁcant break in helical geometry. The characterization of
an 11 change in helical tilt with such clarity is a measure of
the sensitivity of these orientational restraints to structural
deformations. Conversely, the high quality ﬁt of the experi-
mental data in the dipolar and chemical shift waves docu-
ments the structural uniformity of the a-helical fragments. It
is clear that the structure is a well-deﬁned a-helix with 3.66
0.1 residues per turn between residues 26 and 43 for which
we have experimental data.
The kink site of M2-TMD bound with amantadine is in the
immediate vicinity of Gly34. Glycines are known to play
critical roles in transmembrane helices. Kinks have been as-
sociated with glycines in several other transmembrane he-
lices such as Gly99 of KcsA (50). Glycines also are critical in
the formation of tightly packed helices that form coiled coil
structures such as the glycophorin dimer (51).
The ﬁrst experimentally determined structure for M2-
TMD had helices tilted 38with respect to the bilayer normal
(PDB code 1mp6 (14), PDB code 1nyj (11)). While early
reports stated that the helical tilt of M2 was an intrinsic prop-
erty of the protein and hence independent of the hydrophobic
thickness of the bilayer (10), it has recently been shown (52)
that hydrophobic thickness can play a signiﬁcant role in
determining helical tilt, particularly for broader ranges of
thickness. The binding of a ligand can also inﬂuence helical
tilt. However, comparative analysis of tilt with and without
ligand in the present study is complicated by the presence of
amantadine and the use of a different sample preparation
protocol in which the aligned ﬁlm was formed from pre-
formed liposomes rather than a dried ﬁlm from organic
solvents. Preliminary data presented here for ﬁve-site leucine
15N labeled sample without amantadine (top, Fig. 2 C)
suggests a tilt that is substantially less than 38, but obtaining
a full data set in the absence of amantadine has proved dif-
ﬁcult due to broad resonance linewidths. In any event, the
tetrameric bundle appears to possess considerable plasticity,
so that different environmental conditions or sample history
can yield different conformations. This plasticity may play a
role in establishing stability, as the various conformations
that have been observed are exceptionally well-deﬁned and
reproducible.
FIGURE 8 (A) Tetrameric model of M2-
TMD backbone atoms with His37 and Trp41
side chains in the presence of amantadine
(amantadine not shown). The model exhibits
C4 symmetry and reﬂects a minimal helix-helix
interaction of the monomer with a pore diam-
eter of ;10 A˚. The interfacial region is less
a-helical, which may be a result of amantadine
interactions. (B) A top view of tetrameric
complex with a representative radially sym-
metric positioning of amantadine (shown in
orange with amino group pointing away). (C)
The channel width between monomer back-
bone atoms as a function of membrane layer
depth shows a widening near the C-terminus
(bottom).
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